CME Group Inc.

NasdaqGS:CME Lagerbericht

Marktkapitalisierung: US$104.5b

CME Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

CME Group wird ein jährliches Gewinn- und Umsatzwachstum von 3.3% bzw. 4.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.9% betragen.

Wichtige Informationen

3.3%

Wachstumsrate der Gewinne

4.65%

EPS-Wachstumsrate

Capital Markets Gewinnwachstum11.8%
Wachstumsrate der Einnahmen4.7%
Zukünftige Eigenkapitalrendite15.87%
Analystenabdeckung

Good

Zuletzt aktualisiert07 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Analyse-Update • Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Seeking Alpha • Apr 23

CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive

Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking Alpha
Analyse-Update • Apr 11

CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes

The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.
Analyse-Update • Mar 26

CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix

Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.
Analyse-Update • Mar 11

CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook

Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.
Analyse-Update • Feb 25

CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook

The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.
Analyse-Update • Feb 10

CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook

The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.
Analyse-Update • Jan 27

CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook

The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.
Analyse-Update • Jan 12

CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook

Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.
Analyse-Update • Dec 27

CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks

Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.
Analyse-Update • Dec 13

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.
Analyse-Update • Nov 16

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.
Seeking Alpha • Apr 27

CME: More Market Volatility Equals More Demands - Initiating With Strong Buy

Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

CME Group At A New All-Time High - Valuation Concerns Justified?

Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

CME Group: High Quality With Good Dividend Yield

Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CME - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20287,7274,5135,2155,1867
12/31/20277,3304,4254,9094,93112
12/31/20267,0414,3894,6274,66512
3/31/20266,7444,2454,3294,420N/A
12/31/20256,5074,0214,1944,277N/A
9/30/20256,3853,7174,0844,161N/A
6/30/20256,4333,7214,1074,196N/A
3/31/20256,2743,5813,8263,914N/A
12/31/20246,1203,4823,5973,691N/A
9/30/20246,0343,4223,6283,717N/A
6/30/20245,7883,2623,4923,571N/A
3/31/20245,6163,1573,3633,444N/A
12/31/20235,5793,1863,3773,454N/A
9/30/20235,3383,0113,3113,391N/A
6/30/20235,2282,9423,1083,192N/A
3/31/20235,1042,8283,0783,159N/A
12/31/20225,0192,6572,9663,056N/A
9/30/20224,8332,6332,6502,743N/A
6/30/20224,7152,8892,6162,717N/A
3/31/20224,6572,7452,4772,599N/A
12/31/20214,6902,6172,2752,402N/A
9/30/20214,6302,4352,2252,394N/A
6/30/20214,6001,9201,8882,074N/A
3/31/20214,6031,9132,3782,561N/A
12/31/20204,8842,1052,5182,716N/A
9/30/20204,9112,1512,5812,775N/A
6/30/20205,1092,3753,0713,274N/A
3/31/20205,2002,3862,5212,761N/A
12/31/20194,8682,117N/A2,673N/A
9/30/20194,9592,033N/A2,464N/A
6/30/20194,5881,808N/A2,236N/A
3/31/20194,3771,860N/A2,285N/A
12/31/20184,3091,962N/A2,441N/A
9/30/20183,9734,516N/A2,391N/A
6/30/20183,9594,413N/A2,316N/A
3/31/20183,8244,262N/A2,057N/A
12/31/20173,6454,063N/A1,751N/A
9/30/20173,6581,498N/A1,801N/A
6/30/20173,6091,662N/A1,773N/A
3/31/20173,5901,566N/A1,732N/A
12/31/20163,5951,534N/A1,732N/A
9/30/20163,4961,452N/A1,607N/A
6/30/20163,5051,340N/A1,591N/A
3/31/20163,4181,284N/A1,626N/A
12/31/20153,3271,247N/A1,533N/A
9/30/20153,3541,262N/A1,644N/A
6/30/20153,2661,192N/A1,414N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CMEDas prognostizierte Gewinnwachstum (3.3% pro Jahr) liegt unter der Sparquote (3.5%).

Ertrag vs. Markt: CMEDie Erträge des Unternehmens (3.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.6% pro Jahr).

Hohe Wachstumserträge: CMEDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CMEDie Einnahmen des Unternehmens (4.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.5% pro Jahr).

Hohe Wachstumseinnahmen: CMEDie Einnahmen des Unternehmens (4.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CMEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.9%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/07 22:08
Aktienkurs zum Tagesende2026/05/07 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

CME Group Inc. wird von 34 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Stephen BiggarArgus Research Company
Benjamin BudishBarclays
Roger FreemanBarclays